Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The hypothesis that effects of vasoactive intestinal peptide (VIP) on human renal function are mediated via a specific intrarenal VIP receptor was investigated by measuring 125I-VIP binding in plasma membranes isolated from human kidney tissue excised for therapeutic reasons (transitional cell carcinoma, hypernephroma). Equilibrium binding of 125I-VIP was determined by a rapid filtration technique. Specific binding was saturable and showed evidence of both a high affinity binding site (K0.5 range 1.3-12.7 nM; Bmax range 4-56 fmol/mg) and another site of lower affinity. 125VIP binding was partially displaced by homologous peptides and by the VIP antagonist (4CL-D-Phe6,Leu17)-VIP. Distribution of 125I-VIP binding was established using autoradiography: specific binding was confined to the cortex. Such evidence of specific VIP binding, together with our previous report showing VIP stimulation of renal cortical plasma membrane adenylate cyclase, is consistent with a role for VIP in regulation of urine electrolyte composition in the human.


Journal article


Miner Electrolyte Metab

Publication Date





372 - 376


Autoradiography, Humans, Iodine Radioisotopes, Kidney Cortex, Protein Binding, Vasoactive Intestinal Peptide